The
Antibody Drug Conjugates Market involves antibodies that are attached or
conjugated to biologically active drugs or drug warheads through chemical
linkers. ADCs function by selectively delivering cytotoxic, or cell-killing,
agents to tumors while minimizing toxicity to normal tissues. This targeted
approach is known to increase efficacy without exacerbating toxicity.
The global antibody drug conjugates market is
estimated to be valued at US$ 7.02 Bn in 2024 and is expected to exhibit a CAGR
of 14.2% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Antibody Drug Conjugates market are AstraZeneca
PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis
Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc.,
Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd.,
BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd.,
ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento
Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical
Company Ltd.
The key opportunities in the market include increasing demand for targeted
cancer therapies and rising R&D investments by various pharmaceutical
companies in developing ADC drugs. Technological advancements such as
site-specific conjugation of drugs to antibodies help in overcoming challenges
related to conventional drug conjugation methods and improve cytotoxic
potential of ADC drugs.
Market Drivers
The rising demand for targeted cancer therapies, growing R&D expenditure by
pharmaceutical and biopharmaceutical companies, increasing focus on the
development of ADC drugs with novel linkers and warheads, and technological
advancements in antibody conjugation techniques are some of the key factors expected
to drive the growth of the global antibody drug conjugates market during the
forecast period. With increasing investments and improving technologies, ADCs
are poised to play a crucial role in the management of various cancer types in
the coming years.
The
Antibody
Drug Conjugates Market Size faces several challenges that hinder its
growth. One of the major challenges is the complexity involved in the
development and manufacturing of ADC drugs. Linkers and payloads used in these
drugs are highly complex molecules and even minor changes can affect their
efficacy and safety. Developing the right combination of antibody, linker and
cytotoxic agent is challenging.
Another big challenge is the heterogeneity of ADC drugs. During manufacturing,
ADC drugs contain mixtures of payloads attached at different sites and
stoichiometries, making their characterization difficult. Ensuring consistency
and reproducibility across different batches poses difficulties.
The high cost of development is also a major roadblock. Developing an ADC drug
requires expertise across multiple disciplines like molecular biology, protein
engineering and medicinal chemistry. This extensive R&D coupled with
challenges in manufacturing drives up costs significantly. Commercializing such
an expensive drug is risky for companies.
Many ADC drugs also face pharmacological challenges. They have shorter
half-lives compared to conventional drugs requiring higher and more frequent
dosing. Payloads can be released prematurely in the body before reaching the
tumor site reducing efficacy. Ensuring stability of the drug conjugate until it
reaches the target site is difficult to achieve.
Toxicities resulting from the potent payloads also pose safety concerns.
Non-specific release of cytotoxic agents leads to off-target effects damaging
healthy tissues. Developing toxins that are selective only towards tumor cells
while avoiding healthy tissues is a major scientific challenge.
These complexities and risks associated with ADC development lengthen the time
taken to get these drugs through clinical trials and gain regulatory approvals.
Overcoming the scientific and technical barriers is crucial for the growth of
this innovative class of oncology drugs.
Explore
More Related Article on – Immunotherapy
Drugs Market
Get More Insights—Access the Report in the Language
that Resonates with You.
About Author:
Money Singh is a seasoned content writer with over
four years of experience in the market research sector. Her expertise spans
various industries, including food and beverages, biotechnology, chemical and
materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Comments
Post a Comment